	Department: Medical Legal		Page
	Title: Policy – TRALI Mitigation		1 of 2
	Written By: L. Boudreaux	Date:	11/27/2023

TRALI Policy


The Blood Center follows current industry guidelines to reduce the risk of Transfusion Related Acute Lung Injury (TRALI) in recipients who receive high volume plasma products.

- Allogeneic or directed donors must answer the following questions on the Donor Registration Record (DRR).

All Donors:

- Have you ever been pregnant?
 - Are you pregnant now?
 - Have you ever had a blood transfusion?
-

- High volume plasma products and whole blood for allogeneic transfusion should be from
 - Donors who have never been transfused with cellular blood products
 - Donors who have been transfused with cellular blood products and have been tested for HLA antibodies since their most recent transfusion and results interpreted as negative
 - Donors who have not been pregnant
 - Donors who have been pregnant and have been tested for HLA antibodies since their most recent pregnancy and results interpreted as negative
- If either question is answered in the affirmative by a donor, the following blood products will not be produced unless the donor has been screened for HLA Antibodies and results interpreted as negative
 - Fresh Frozen Plasma (FFP) obtained from whole blood
 - FFP obtained from apheresis
 - plasmapheresis
 - plasma collected concurrently with a cellular component (red cells or platelets)
 - Plasma, Cryoprecipitate Reduced (i.e., Cryo-poor plasma) obtained from whole blood
 - Plasma Frozen Within 24 Hours After Phlebotomy (PF24) obtained from whole blood or apheresis

	Department: Medical Legal		Page
			2 of 2
	Title: Policy – TRALI Mitigation		
Written By: L. Boudreaux		Date: 11/27/2023	

- Plasma Frozen Within 24 Hours After Phlebotomy Held At Room Temperature Up To 24 Hours After Phlebotomy (PF24RT24) obtained from apheresis
- Thawed Plasma from any of the above products
- Liquid Plasma
- Whole Blood (if designated for transfusion as whole blood rather than for component preparation)
- **Donors testing reactive for HLA antibodies are deferred from donating high volume plasma products** and are notified by the Medical/Legal Department of their donation status.
- **Donors with blood products implicated in a possible TRALI case and, upon testing are found to be reactive for anti-HLA antibodies, are permanently deferred from allogeneic blood donations.**
- **Donors who are the only provider of blood components to a patient with a suspected case of TRALI, and do not test reactive for anti-HLA antibodies, are permanently deferred from allogeneic blood donations if determined as such following Medical Director review.**
- The Blood Center will manufacture Recovered Plasma for further manufacturing.

Document Change Control:

() Major Change (Change Control & Risk Analysis Required)		Change Control Submission Date:
Department:	Submitted By:	Change Control Number: